C2 PHARMA receives DMF approval in China for pilocarpine nitrate

Published: 22-Nov-2023

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil

Pilocarpine nitrate is an ophthalmic API extracted from the Jaborandi plant and is primarily used to treat glaucoma and other specific diagnostic applications.

C2 PHARMA is the main supporter of the "Partnership for a Better World" initiative to drive sustainable principles and ecofriendly harvesting practices of the Jaborandi plant in the wild, which emphasises a commitment to prioritising the overall well-being of farming communities and the environment.

The initiative underscores C2 PHARMA's active contribution to a more sustainable future in pharmaceutical API production.

“After a rigorous 4-year journey, we are proud to have met numerous requests from the Chinese Health Authorities (CDE) and are finally able to provide this API to the Chinese market,” stated Regulatory Affairs Manager, Anastasia Motorina.

“Collaboration was truly key here with our manufacturing partner, Anidro do Brasil, to implement the CDE requirements along with the help of our partner Guangzhou Greensyn.” 

Trending Articles

Relevant companies

You may also like